Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't have PM but ditto that. I am just a regular old schlep with a 9 to 5 and no team. I probably should avoid penny stocks but my personality needs the input.
Unfortunately, that means I am a multi-stock bag-holder.
This one, I am holding some for $20/share or bust!
Not trying to start anything. This needs to more negative pub. .30 good long-term tuck it away though.
That is true. Point taken.
Not anytime soon.
I saw 9:30 this morning and the ask was higher than now all day.
Anyone that bought on the ask after you featured it is in the red today unless they flipped early.
Stop the fluffy math.
One day...
Remove this sticky already. The links don't work.
You know....RAMO Expected Price Per Share .63-$3.09, per PPA's
I'm bored, it was only $20
How about that tap?
What? Are they going to rocket up the ask and nudge the bid by .0005 until they get some sellers?
They need to up that bid!
There's a tap. Tried 150k but they wouldn't fill it but I changed it 100k and it went right away.
Good morning!
Bologne. Just a morning shake-out. Look back at 10:30. Not if, but WHEN they get that first contract...
With pennies, always assume the worst. They are dumping IMO.
Whoa, I am an assistant! thanks rw!
CVM, CVM, CVM,... Just curious, what are the qualifications to get in the top boards?
Like if this one has a couple a day and then we finally get something GOOD to chew on that gets attention will it show up?
The other day when we had news the board had a "big" increase but I guess the average for 7 days was 0. No good.
Things that make you go hmmmmm...
Don't start drifting the wrong way now...hold the upper 30s.
yeah, like me. baaaaa
Ok, approval. If this thing makes it that far it would mean great things and a share price double digit multiples beyond today's share price.
They do get revenue for batches created for pIII sites don't they?
Going to keep a couple posts a day on this board.
That's a long time. If results REALLY are positive, word will get out and wouldn't more folks with this type of cancer WANT to be involved?
volume is not that bad
Just slow at hitting their milestones. I don't think it is years before data starts coming in. The share price will increase in time.
Yep, things finally coming together.
CVM is going to breakout today! CVM, CVM, CVM.
what? New news today not already posted here.
Yeah buddy!
CEL- SCI Corp. Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Inj...
Today : Wednesday 2 November 2011
CEL-SCI Corporation (NYSE AMEX: CVM) provided an update today of the progress of its Phase III clinical trial of Multikine (Leukocyte Interleukin, Injection)*, which is currently being investigated in an open-label, randomized, controlled, multi-center study. Notable highlights include:
* Arrangements have been completed with leading clinical investigators and institutions from 8 countries on 3 continents to conduct the study. So far thirty five (35) clinical centers have met all legal, regulatory, and protocol requirements to screen and enroll patients. Ten of these centers in the study are controlled by CEL-SCI's partners Teva Pharmaceuticals Industries Ltd. (Israel) and Orient Europharma (Taiwan). Both companies manage their parts of this Phase III trial under procedures provided by CEL-SCI’s global Clinical Research Organization (CRO). CEL-SCI is currently arranging to bring on line an additional 10 centers to ensure rapid enrollment of the study.
* MD Anderson Radiological Physics Center, the contractor that CEL-SCI hired to assess that each clinical center is adequately equipped to accurately and precisely deliver the radiotherapy dosage regimen prescribed by CEL-SCI’s protocol to the study subjects as part of their standard care and assess that each center has an established a satisfactory Radiotherapy Quality Assurance (RTQA) program so as to assure that the radiotherapy delivered to the subjects which meets the requirements of our Phase III protocol and is consistent and comparable between patients and centers worldwide, has concluded its assessment of all 35 clinical centers. Each center has demonstrated these capabilities to the satisfaction of MD Anderson Radiological Physics Center.
* CEL-SCI has produced multiple lots of its investigational therapy Multikine (Leukocyte Interleukin, Injection) for the Phase III trial in its manufacturing facility and has supplied the product to the clinical sites in the U.S. and Canada, and six other countries around the world. CEL-SCI has sufficient manufacturing capacity in its manufacturing facility to produce the entire drug supply that will be needed for all the subjects in the trial who will receive Multikine.
* The cold chain distribution and storage methods used during shipping and storing Multikine at the clinical centers have been established and validated, and also tested in numerous shipments of Multikine around the world.
* Multiple subjects have been enrolled in the Phase III trial and have received either Multikine followed by standard therapy (surgery followed by radiation or surgery followed by radiation plus chemotherapy), or only standard therapy, the control group for the Phase III trial.
* The Company also extended the existing licensing agreements with Teva Pharmaceuticals to include the countries of Croatia and Serbia.
* CEL-SCI also entered into a licensing agreement with IDC-GP Pharm for Argentina and Venezuela.
"We are pleased by the progress we have made in moving this study forward. Having brought on-line 35 clinical centers in 8 countries on 3 continents in less than one year took great effort," said Geert Kersten, CEL-SCI's Chief Executive Officer. “With this work behind us, enrollment is accelerating and will hopefully continue to accelerate further. While it may have taken somewhat longer to set this study up on three continents than it would have taken if the study were run only in the US, the demographics of the disease we are attempting to treat with Multikine are such that the study could not be enrolled and completed in a reasonable period of time if the study were conducted only in the U.S. By conducting the study in countries that have many more patients concentrated in fewer clinical centers, enrollment should be much faster and result in a reduction in the time required to complete the study. There will also be the added benefit that includes the acceptance of the study results from a study which has tested Multikine on a diverse world-wide population.”
CEL-SCI’s Phase III study is designed to determine if Multikine (Leukocyte Interleukin, Injection) investigational therapy administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Radiochemotherapy) used for the treatment naive (yet untreated) subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
y, whoever is selling they want more than .0001! Hell, I will add to 10 million if they gave me 2s.
C'mon man, sheesh. This is getting old. Buy them up and the ask may raise. Won't raise the bid to shake out any "weak" hands because shares are being dumped on us.
That is why no one "knows" about this stock. Unfortunately, I was new and got myself in it.
randysads...I am new but isn't that free garbage any pinky speculator can post? I have not seen any other reference to that in my 10months casually reading IHUB.
So they say. I just don't buy that. Every time you all chew up some 4s, a big chunk appears.
Waiting, waiting, waiting....no patiently but holding.
I have 7.5m but to me that just makes me believe you have the float wrong and more is getting dumped on us. JMHO.
oh my, here comes the bs we are up 80%.
What about November, it's almost here?
C'mon man! Let's break through .40!
All kinds of speculation there. We are long overdue for an update. Probably will see shares dumping at .40.